MSIRus22: Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer
Study Details
Study Description
Brief Summary
Prospective multicenter registry study to assess the frequency of Lynch syndrome among patients with colorectal cancer in Russia
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Blood and tumor samples will be obtained from enrolled patients. 4 ml of venous blood samples will be taken into a tube with EDTA and stored at -20 0C. Tumor samples will be taken during endoscopy or surgical treatment, embedded in paraffin and stored at room temperature.
Microsatellite instability in the tumor tissue will be determined by any method available in the participating center (immunohistochemical or molecular genetic study). In case of detection of microsatellite instability/deficiency in the repair system of unpaired bases blood samples will be analyzed for the fact that germinal mutations in the DNA mismatch repair genes.
Patients will be followed up for 5 years after enrollment. During follow up correlation of spectrum of germinal mutations with clinical data, effectiveness of therapy with immune checkpoint inhibitors, the spectrum of malignant neoplasms in the families of patients with Lynch syndrome, the impact of the presence of microsatellite instability/deficiency in the DNA mismatch repair genes on treatment tactics in the Russian Federation will be assessed.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Patients with colorectal cancer Patients with colon adenocarcinoma who have not previously received antitumor treatment (chemo/radiation therapy) for a currently detected tumor |
Outcome Measures
Primary Outcome Measures
- Frequency of microsatellite instability and Lynch syndrome [up to 5 years]
To assess the frequency of microsatellite instability and Lynch syndrome in the population of patients with colorectal cancer in the Russian Federation.
Secondary Outcome Measures
- Frequency of occurrence of microsatellite instability/deficiency [up to 5 years]
Assessment of the frequency of occurrence of microsatellite instability/deficiency in the repair system of unpaired bases in second tumors in patients with colorectal cancer of various stages.
- Spectrum of germinal mutations in Lynch syndrome [up to 5 years]
The mlh1, msh2, msh6, pms2 and epcam genes will be examined for the presence of all types of pathogenic variants in patients with MSI in colon tumor. The possible correlation of gene-phenotype and pathogenic variants of each gene-phenotype will also be studied. To detect MSI in a tumor sample, need to do the fragment analysis (markers NR21, NR24, NR27, BAT25, BAT26). Рatients with MSI in the tumor will have DNA diagnostics of MMR EPCAM genes by sequencing and MLPA . The MMR and EPCAM genes will be examined in DNA isolated from blood lymphocytes.
- Spectrum of malignant neoplasms [up to 5 years]
The family history of all oncological diseases will be studied to find out the main target organs of patients with Lynch syndrome in Russia
- Effectiveness of therapy with immune checkpoint inhibitors [up to 5 years]
The frequency will be compared: the frequency of objective response rate (RECIST 1.1) while using immune checkpoint inhibitors in metastatic colon cancer and microsatellite instability associated/not associated with Lynch syndrome
- Impact of the presence of microsatellite instability/deficiency [up to 5 years]
The frequency of adjuvant chemotherapy in stages II-III of colon cancer in the presence of microsatellite instability / deficiency in the repair system of unpaired bases in real clinical practice will be evaluated
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Provision of written informed consent;
-
Patients with histologically verified colon adenocarcinoma or patients with histologically verified synchronous neoplasms who have not previously received treatment for a second tumor;
-
Age ≥ 18 years;
-
Absence of antitumor treatment for a real tumor (it is allowed to include patients who have a history of antitumor treatment for other malignant tumors, if the period after treatment is more than 12 months).
-
The ability of the patient, according to the Researcher, to fulfill the requirements of the Protocol;
Exclusion Criteria:
- Patients receiving chemotherapy or radiotherapy for colon cancer at the time of screening
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | State Scientific Centre of Coloproctology | Moscow | Russian Federation | 123423 |
Sponsors and Collaborators
- State Scientific Centre of Coloproctology, Russian Federation
- The Loginov MCSC MHD
- Pirogov National Medical and Surgical Center
- Moscow City Oncological Hospital No. 62 MHD
- City Clinical Oncological Hospital No. 1 MHD
- MMCC Kommunarka MHD
- D.D. Pletnev City Clinical Hospital MHD
- Botkin Hospital MHD
- Clinic K+31
Investigators
- Principal Investigator: Alexey Tsukanov, PhD, Head of the Department of Laboratory Genetics
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 01082022